Combining Abiraterone, Niraparib, and Prednisone for Prostate Cancer Treatment
This patent describes a new way to treat prostate cancer by combining three specific medications: abiraterone acetate, niraparib, and prednisone.
Original patent title: “Treatment of prostate cancer with a combination of abiraterone acetate, niraparib tosylate monohydrate and prednisone”
This patent describes a new way to treat prostate cancer by combining three specific medications: abiraterone acetate, niraparib, and prednisone. Granted in 2026.
Coverage
What does this patent actually cover?
This patent describes a method for treating prostate cancer using a specific combination of three drugs: abiraterone acetate, niraparib, and prednisone. The disclosure covers both giving these drugs separately (free-dose) or together in a single pill (fixed-dose). The goal is to use these medicines in combination to fight prostate cancer. For example, a doctor might prescribe a patient with prostate cancer a daily regimen that includes all three of these medications to work together against the disease.
The gap
What does this patent NOT cover?
- Does not cover treating prostate cancer with only one or two of the specified drugs, rather than the full combination of abiraterone acetate, niraparib, and prednisone.
- Does not cover using different drug combinations to treat prostate cancer.
- Does not cover treating other types of cancer, such as breast cancer or ovarian cancer, with this drug combination.
- Does not cover methods of treating prostate cancer that do not involve the specific combination of abiraterone acetate, niraparib, and prednisone.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The clever bit is identifying that combining abiraterone acetate, which blocks hormone production, with niraparib, which interferes with cancer cell DNA repair, along with prednisone, could create a more powerful and effective treatment strategy for prostate cancer. This specific combination aims to attack the cancer from multiple angles simultaneously.
Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Abiraterone acetate (marketed as Zytiga)
Niraparib (marketed as Zejula)
Prednisone
Future fixed-dose combination therapies for prostate cancer
Why it matters
The bigger picture
Prostate cancer is a common and serious disease, and finding more effective treatments is crucial. This patent matters because it proposes a specific combination of known drugs, abiraterone acetate and niraparib, along with prednisone, to potentially improve patient outcomes. Such combinations can target cancer through multiple pathways, which may lead to better results or help patients who have become resistant to single-drug therapies.
Filed
May 7, 2021
Granted
September 15, 2026
Market context
Who's building on this
Companies in this space
Companies active in oncology, particularly those developing treatments for prostate cancer, are likely exploring similar combination therapies. Janssen Biotech, which markets abiraterone acetate, and GSK, which markets niraparib, are major players in this space and would be interested in optimizing their drug portfolios through new combinations.
Market impact
As this patent was filed recently in 2021 and granted in 2026, its direct market impact is still developing. If clinical trials prove the combination effective, it could lead to a new standard of care for prostate cancer, potentially enabling new product lines for pharmaceutical companies and offering an improved treatment option for patients.
Claim 1 — Plain English
What this patent covers
This patent describes a method for treating prostate cancer using a specific combination of three drugs: abiraterone acetate, niraparib, and prednisone. The disclosure covers both giving these drugs separately (free-dose) or together in a single pill (fixed-dose). The goal is to use these medicines in combination to fight prostate cancer. For example, a doctor might prescribe a patient with prostate cancer a daily regimen that includes all three of these medications to work together against the disease.
The clever bit
The clever bit is identifying that combining abiraterone acetate, which blocks hormone production, with niraparib, which interferes with cancer cell DNA repair, along with prednisone, could create a more powerful and effective treatment strategy for prostate cancer. This specific combination aims to attack the cancer from multiple angles simultaneously.
What it does not cover
- Does not cover treating prostate cancer with only one or two of the specified drugs, rather than the full combination of abiraterone acetate, niraparib, and prednisone.
- Does not cover using different drug combinations to treat prostate cancer.
- Does not cover treating other types of cancer, such as breast cancer or ovarian cancer, with this drug combination.
- Does not cover methods of treating prostate cancer that do not involve the specific combination of abiraterone acetate, niraparib, and prednisone.
Patent timeline
Application submitted to the patent office
Patent officially issued
PatentBrief Score
Impact Score
Early stage
Citation count
0/40
No citations yet
Claim breadth
0/20
Narrow claimsclaimsThe numbered statements at the end of a patent that legally define what the inventor owns.Read more →
Recency
20/20
Granted within 5 years
Assignee scale
0/20
Independent or smaller assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$36K – $115K
Midpoint $72K · 14.6 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
Concepts involved
Cite this patent
(2026). Combining Abiraterone, Niraparib, and Prednisone for Prostate Cancer Treatment (U.S. Patent No. 12,734,180). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/12734180/treatment-of-prostate-cancer-with-a-combination-of-abiraterone-acetate
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US12734180"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does Combining Abiraterone, Niraparib, and Prednisone for Prostate Cancer Treatment cover?
This patent describes a new way to treat prostate cancer by combining three specific medications: abiraterone acetate, niraparib, and prednisone.
When does this patent expire?
This patent is expected to expire on September 15, 2046, when the invention enters the public domain.
What problem does this patent solve?
Prostate cancer is a common and serious disease, and finding more effective treatments is crucial. This patent matters because it proposes a specific combination of known drugs, abiraterone acetate and niraparib, along with prednisone, to potentially improve patient outcomes. Such combinations can target cancer through multiple pathways, which may lead to better results or help patients who have become resistant to single-drug therapies.
What does this patent NOT cover?
Does not cover treating prostate cancer with only one or two of the specified drugs, rather than the full combination of abiraterone acetate, niraparib, and prednisone.
Patent monitoring